首页> 外国专利> 5,7,3'-Tri:hydroxy-4'-methoxy-flavone ether(s)

5,7,3'-Tri:hydroxy-4'-methoxy-flavone ether(s)

机译:5,7,3'-三:羟基-4'-甲氧基-黄酮醚

摘要

Water-soluble hydroxy-flavone ethers are novel cpds. comprising 5-R10- 7-R0-3'-R2-4'-methoxy-flavones of formula (I) (where R is H, -CH2-CH2-OH or 6-O-alpha-L-rhamnosyl-D-glucosyl; R1, R2 independently are H or -CH2-CH2-OH. In the broadest definition (not claimed) -CH2-CH2-OH groups are changed to substd-alkyl.) Used to treat vascular permeability and fragility by oral, rectal, parenteral or topical admin. in doses of 50-300 mg 3-8 times daily. In capillary fragility tests (Charlier et al technique) (I) show equal to superior activity to diosime and superior activity to ruten. They are used to treat venous troubles, such as varicose and haemorrhoidal troubles, haemorrhagic diatheses and purpura, retinopathies and arteriolites in hypertension and diabetes, gastro-duoderal ulcers, ulcerocas colitis, metrorrhages etc.
机译:水溶性羟基黄酮醚是新型的cpds。包含式(I)的5-R10-7-R0-3'-R2-4'-甲氧基-黄酮(其中R是H,-CH2-CH2-OH或6-O-α-L-鼠李糖基-D-葡萄糖基; R1,R2独立地为H或-CH2-CH2-OH。在最广泛的定义(未要求保护)中,-CH2-CH2-OH变为亚烷基。)用于口服和直肠治疗血管通透性和脆弱性,肠胃外或局部用药。剂量为50-300毫克,每日3-8次。在毛细管脆性试验(Charlier等人的技术)中,(I)显示出与二碘肟相比具有更好的活性,而与ruten则具有相同的活性。它们用于治疗静脉疾病,例如静脉曲张和痔疮疾病,糖尿病和紫癜的出血性出血,视网膜病变和小动脉粥样硬化,高血压和糖尿病,胃十二指肠溃疡,溃疡性结肠炎,大出血等。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号